Aim: DNAs containing unmethylated CpG motifs can stimulate innate and adaptive immunity. The aim of this study was to investigate the immunostimulatory and anti-neoplasm effects of a novel CpG oligodeoxynucleotide, ODN10, in tumor-bearing mice. Methods: B16 melanoma-bearing C57BL/6 mice were administered ip or sc with ODN10 or conventional CpG ODN1826 on the indicated days post inoculation. The animal survival rate and the inhibitory effect on tumor growth were observed in vivo. B and T lymphocyte proliferation, natural killing cell cytotoxicity and the phagocytic ability of peritoneal macrophages from the animals were determined using [
Introduction
The immune system of vertebrates is comprised of two complementary systems, the innate and the adaptive. In the innate system, dendritic cells (DCs) are the major antigen presenting cells to T h0 T cells in lymph nodes that polarise into T h1 and T h2 cells, which subsequently produce different cytokines. Polarised T h1 cells produce interleukin (IL)-2, IL-12, and interferon (IFN)-γ, while polarised T h2 cells produce IL-4, IL-5, IL-6, IL-10, and IL-13. In healthy individuals, there is a T h1 /T h2 cytokine balance, whereas in the tumor-bearing individual, T h2 cytokine # The first three authors contributed equally to this work. * To whom correspondence should be addressed.
E-mail songhf@vip.163.com Received 2011-11-03 Accepted 2012-04-23 synthesis is increased. As such, researchers have tried to upregulate the T h1 population and maintain the balance of T h1 /T h2 to reverse the abnormal immune status in tumor patients [1] . Bacterial and synthetic DNAs containing unmethylated CpG motifs were known to stimulate innate and adaptive immunity due to their interesting immunostimulatory properties in a number of vertebrates. The recognition of CpG DNAs by immune cells was mediated by Toll-like receptor 9 (TLR9), a receptor mainly expressed by B cells and plasmacytoid DC cells in humans and macrophages in mice [2] . TLR9-stimulated immune cells showed increased expression of co-stimulatory molecules, resistance to apoptosis, and up-regulation of T h1 -promoting chemokines and cytokines such as IL-2, IL-12, and IFN-γ [3] . In vivo, CpG DNAs were strong T h1 -inducing adjuvants [4] [5] [6] [7] [8] . Recently, CpG oligodeoxynucleotide (ODN)s have been explored for use as an anti-cancer therapy due to their immunostimulatory properties, such as inducing the release of large amounts of type I IFN, inhibition of the synthesis of T h2 cytokines, induction of T h1 cytokine synthesis, and the activation of NK cell cytotoxicity or cytotoxic T lymphocyte (CTL) precursors into anti-tumor CTL cells [9] [10] [11] [12] [13] . Further, CpG ODNs enhanced the anti-tumor efficacy of monoclonal antibodies or cancer vaccines when used as an adjuvant in animal tumor models [11, 14] . CpG ODNs alone were also capable of triggering potent anti-tumor immune responses against various experimental tumors, for example, lymphoma, melanoma, colon tumor, glioma, and neuroblastoma [15] [16] [17] [18] [19] [20] [21] . We previously investigated the relationship between primary and secondary structures of CpG ODNs and their immunostimulatory effects on murine spleen cells and found that specific structures of CpG ODNs could vary greatly in their ability to induce host immunity in mice [22] . We screened several novel CpG ODN sequences to identify those with superior immunostimulatory activities relative to the conventional linear control CpG ODN1826, which is a strong immune activator that induces protective and curative T h1 responses against infections and tumors in vivo in mice [9, 20, 21, [23] [24] [25] . Among them, ODN10, which possessed a holistic, self-complementary palindrome structure and promised the strongest immunostimulatory potential, was chosen for use in the present study. The immunostimulatory potential of ODN10 was evaluated by its activation of NK cells, T cells, B cells, macrophages, and the helper T cell related cytokine secretion profile in malignant melanoma-bearing mice. To characterise the most important outcome of immunomodulatory therapy, the in vivo anti-tumor efficacy of ODN10 was investigated as well. The results suggested that ODN10, a novel CpG ODN with self-palindrome structure, displayed outstanding anti-tumor activity superior to that of other conventional CpG-containing immunostimulatory ODN sequences. In addition, the anti-tumor activity of ODN10 may be attributed to its powerful immunoregulatory potential to reverse established T h2 -type responses to a T h1 -type response.
Materials and methods

CpG ODNs
Purified, single-stranded, phosphorothioated ODNs containing CpG motifs were synthesised by Sangon Biotech Company (Shanghai, China). The CpG ODNs used in this study were as follows: ODN10, 5'-TCCATGACGTTTTAAAACGTCATG-GA-3', ODN1826, 5'-TCCATGACGTTCCTGACGTT-3', nonCpG ODN control, 5'-TGCTGCTTTTGTGCTTTTGTGCTT-3'. Schematic diagrams of the secondary structure of ODN1826 and ODN10 are shown in Figure 1 . All ODNs were diluted in phosphate-buffered saline (PBS) (0.1 mol/mL, pH 7.3) and stored at 4 °C before use.
Cells and cell lines
Spleen cells from 6-to 8-week-old C57BL/6 mice were cultured in RPMI-1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS; GIBCO, Detroit, MI, USA) and antibiotics (100 IU/mL of penicillin and 100 IU/mL of streptomycin). The B16.F1 melanoma cells, which are syngeneic to C57BL/6 mice, were maintained in vitro as previously described [26, 27] . Yeast artificial chromosome-1 (YAC-1) cells were kindly provided by Prof Wen-xia ZHOU (Institute of Pharmacology and Toxicology, Beijing, China).
Experimental animals
Female C57BL/6 mice (6-8 weeks of age, 20.0±2.0 g), were purchased from the Experimental Animal Raising Center of the Academy of Military Medical Sciences (Beijing, China). All animal experiments and protocols were performed strictly in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
Tumor models
Exponentially growing B16.F1 melanoma cells were harvested when their viability exceeded 95%, which was determined by trypan blue staining. The cells were resuspended in 0.2 mL PBS and were injected subcutaneously (sc) at the dosage of 2×10 6 cells/animal into the right axilla of C57BL/6 mouse. The cells resuspended in 0.2 mL PBS were injected intraperitoneally (ip) into another group of individuals at a dose of 2×10 5 cells/animal.
Dose determination
Tumor-bearing mice (sc inoculated) were randomly divided into various treatment groups (10 animals in each group) and then treated ip with PBS or ODN10 on 9, 12, and 15 d post inoculation at the indicated doses (1, 5, or 25 mg/kg). Mice were checked daily for tumor growth. Tumor volume was calculated using the formula 1/2a×b 2 , where a and b are the long and short diameters (in mm), respectively.
Survival assay
Tumor-bearing mice (ip inoculated) were divided randomly into various treatment groups (10 animals in each group). On 0, 3, and 7 d post inoculation and weekly thereafter, the mice received ip treatment of ODN10, ODN1826, or non-CpG ODN and PBS control, with all ODNs administered at the same dos- In vivo inhibitory effect on tumor growth Subcutaneously inoculated tumor-bearing mice were divided randomly into four treatment groups (10 animals in each group) and then treated ip with various ODNs (ODN10, ODN1826, or non-CpG ODN, all at the dose of 5 mg/kg) or PBS on d 9 (when the tumor size reached approximately 5 mm in diameter), 12, 16, and 19 post tumor inoculation. Mice were checked daily for tumor growth, and the mice were sacrificed on d 20 post inoculation, when the tumor size from mice in the PBS control group reached approximately 25 mm on the long diameter. The tumors and spleens were collected from individual animals and weighed. The oxter lymph nodes and the ascites were collected for further study. The serum was collected into 2 mL microtubes and stored at -70 °C until measurement. The inhibitory effect of the ODNs on tumor growth in vivo was evaluated by the tumor growth inhibitory rate (TGI%), which was calculated by the formula (W 0 -W)/ W 0 ×100%, where W represented the tumor weight of the ODNtreated groups, and W 0 was that of the PBS control group.
B and T lymphocyte proliferation assay Proliferation of mouse B cells and T cells from tumor-bearing mice treated with different ODNs or the control, as well nontumor-bearing mice was determined by a [
3 H]-thymidine incorporation assay as described [28] . Briefly, splenocytes (2×10 5 cells) harvested from tumor-bearing mice or the normal mice were loaded in a 96-well culture plate with or without 5 μg/mL ConA or LPS (Sigma, St Louis, MO, US) and cultured at 37 °C in a 5% CO 2 atmosphere in RPMI-1640 for 72 h, with 1 μCi of [ 3 H]-thymidine ([ 3 H]-TdR, Institute of Atomic Energy, Beijing, China) added for the last 18 h. The cells were harvested, and the radioactivity was measured using a microBeta liquid scintillation counter (PerkinElmer, Waltham, MA, USA).
NK-mediated cytotoxicity assay
The NK cytotoxicity of splenocytes was detected with a 4 h 51 Cr release assay as previously described [27] . Briefly, splenocytes were harvested from tumor-bearing mice or nontumor-bearing mice to serve as effector cells. One million YAC-1 cells/well (serving as target cells) were labelled with 50 µCi of 51 Cr for 1 h at 37 °C in a 96-well microplate and were then washed 3 times and incubated for 4 h with effector cells (with an E:T ratio of 50:1). Thereafter, supernatants were harvested, and the radioactivity was measured using a microBeta liquid scintillation counter (PerkinElmer, Waltham, MA, USA). The results are expressed as the mean percentage of specific lysis (triplicate wells)±SD, where percent specific lysis (%)=(experimental countstarget cell spontaneous release counts)/(maximal release counts-target cell spontaneous release counts)×100%. Spontaneous lysis was measured in wells containing only target cells, whereas maximum lysis was measured from the wells containing target cells incubated with 10% SDS.
Macrophage phagocytosis assay
The phagocytic ability of peritoneal macrophages was examined with a neutral red chromometry method strictly as described [29] . The data shown are representative of two replicate experiments.
Cytokines and chemokines ELISAs
Serum IL-12, IL-4, and IgE levels were measured twice by ELISA according to the manufacturer's instructions (IL-12 P40 and IL-4 kits were purchased from R&D Systems (Minneapolis, MN, USA), and the IgE kit was purchased from BETHYL (Montgomery, TX, USA). The plate reader was calibrated to the manufacturer's specifications, and the absorbance (450 nm) of the contents of each well was determined.
Histopathology and immunohistochemistry
After dissection, specimens of tumor, spleen, and oxter lymph nodes were fixed for 1 week in 4% buffered paraformaldehyde, embedded in paraffin, and stained with hematoxylin and eosin (H&E staining). PCNA, CD63, and CD80 expression levels in the tumor tissues were analysed by immunohistochemistry. Briefly, the paraffin-embedded sections were dewaxed and rehydrated. Antigen retrieval was performed in citrate buffer (pH 6.0) using the microwave technique. Endogenous peroxidase activity was quenched by 30% hydrogen peroxide in distilled water for 5-10 min and then washed in PBS. Primary antibodies (mouse anti-mouse monoclonal antibodies against PCNA, rabbit anti-mouse monoclonal antibodies against CD63 and CD80), the Mouse/Rabbit IgG SABC kit, and 3,3'-diaminobenzidine (DAB) solution were purchased from Wuhan Boster Biotechnology (Wuhan, China). Sections were sequentially incubated with primary antibody, the biotinylated anti-mouse/rabbit antibody, and the streptavidin peroxidase reagent. Peroxidase activity was detected with DAB solution. The same process performed without the primary antibody was used as a control. Sections were weakly counterstained with hematoxylin.
Statistical analysis
The data are shown as the mean±SD, and statistical significance was determined with the SPSS (v 10.0) software with Student's t test or analysis of variance (one-way ANOVA). Survival data were analysed by the Mantel-Cox logrank test. P<0.05 was considered to be statistically significant. Figure 3 , on d 22, the survival rates of non-CpG ODN, ODN1826, and ODN10 groups were 0%, 20%, and 70%, respectively, compared with the PBS control group. CpG ODN can significantly prolong the survival of mice with B16 melanoma. ODN10 showed more effectiveness than ODN1826 and its potent antitumor activity in vivo was illustrated again.
Results
Inhibitory effect on tumor growth in vivo
In vivo immunostimulatory activities of ODN10
We investigated the difference between the immune states of the tumor-bearing mice and normal mice, with the measurement indicators included in the study being the proliferation potential of B and T lymphocytes, NK cytotoxicity of splenocytes, and the phagocytic ability of peritoneal macrophages.
The results showed that all of the above-mentioned immune activities were suppressed in tumor-bearing mice compared to their normal counterparts (P<0.05). However, the CpG immunostimulatory sequences significantly reversed the immunosuppression status in tumor-bearing mice. Among them, the ODN10 displayed the most prominent immunostimulatory potential ( Figure 4) . As to the influences on chemokine or cytokine secretion, CpG ODN treatment is known to reverse established T h2 responses to T h1 -type responses [30, 31] . In the present study, IL-12 and the IL-4 were selected as the indicator cytokines, where the former is a T h1 -type cytokine, while the latter is a T h2 -type cytokine. As a result of induction of IL-4, B cells switch to IgE synthesis and inhibit IgG antibody synthesis; therefore, IgE levels in mice were also monitored as a marker of T h1 -T h2 response type conversion. The results showed that in the absence of CpG ODN treatment, serum from tumorbearing mice contained markedly higher IL-4 and IgE levels and lower IL-12 levels than normal mice, suggesting a predominantly T h2 polarisation, while the CpG ODN treatment IgE. Again, ODN10 had more significantly robust immunostimulatory effects compared with ODN1826 ( Figure 5 ). Figure 6 shows the H&E staining of tissue sections from formalin-fixed tumors obtained 20 d after tumor injection. PBS-treated tumors exhibited a solid growth pattern without necrosis. ODN10 treatment could make the tumor cell exhibit extensive cellular polymorphisms, including cavitate nuclei, swollen nuclei, and apoptosis. Figure 7 shows the H&E staining of tissue sections from spleen or oxter lymph nodes. The PBS group presented with large-scale necrosis and vasal infarct by metastatic melanoma masses in the spleen and metastatic melanoma in the vessels of oxter lymph nodes. Both the spleen and oxter lymph nodes were normal in the CpG ODN10 treatment group. PCNA was expressed exclusively in tumor tissues of the melanoma mice, and ODN10 treatment decreased PCNA expression ( Figure 8A-C) . Expression of CD63 ( Figure 8D-F) , a melanoma metastasis-associated antigen, was similar to PCNA. On the contrary, ODN10 could induce expression of 
Pathobiology and immunohistochemistry analysis
Discussion
Bacterial and synthetic CpG DNAs promote B cell proliferation, immunoglobulin production and the secretion of a number of cytokines, including IL-6, IL-12, IFN-α, and IFN-γ, from B cells, monocytes/macrophages, DC cells and NK cells. ODN1826 is known as a strong immune activator that induces protective and curative T h1 responses against infections and tumorigenesis in vivo for mice [10, [23] [24] [25] . Our previous studies showed that ODN10, a novel CpG ODN containing a holistic self-complementary palindrome structure (5'-TCCATGACGTTTTAAAACGTCATGGA-3'), possesses more potent immunostimulatory effects than a conventional CpG ODN (ODN1826), characterised by inducing a high level of IL-12 and IFN-α secretion and potentiating NK cell lytic activity [22] . We presume that their immunostimulatory properties may play roles in the CpG ODN-induced inhibition of B16 melanoma growth.
In our study, we found that the proliferation of B cells and T cells, NK cytotoxicity of splenocytes, and the phagocytic ability of peritoneal macrophages in tumor-bearing mice were lower than those in normal mice. Additionally, we also found that serum from tumor-bearing mice contained markedly higher IL-4 and IgE levels and lower IL-12 levels than normal mice, suggesting a predominantly T h2 polarisation. These phenomena indicated that the burden of the tumor might impair the function of an individual's innate and adaptive immune system. In tumor-bearing individuals, when IL-4, a type of T h2 cytokine, is produced at a higher level than normal, it can induce the IL-4 response genes in T cells and also shut off IgG synthesis by B cells and induce IgE synthesis. Under these conditions, the high T h2 cytokine level is dominant in the individual, an allergy-like inflammatory condition develops, the adaptive immune response is inhibited, and tumor development and progression continue. The increased IgE levels in cancer patients reflect impaired cellular immunity [1] . Our results also showed that the activities of the above-mentioned immune cells increased remarkably from the CpG ODN treatment, especially from ODN10 treatment. Meanwhile, we found that the antitumor activity of CpG ODNs was increased along with their immunomodulatory activity, for example, prolonged survival of mice with B16 melanoma, and inhibition of the tumor growth. Pathobiology and immunohistochemistry analysis also indicated that ODN10 could activate the host anti-tumor immune response to inhibit the in vivo growth and metastasis of melanoma tumors in mice.
Our study showed that ODN10 had potent antitumor activity, which was positively correlated with its superior immunomodulatory effects, including promoting B and T lymphocyte proliferation, enhancing NK cell and peritoneal macrophage activity, inducing IL-12 secretion, and inhibiting IL-4 and Figure 6 . Tumor tissues were fixed in 4% buffered paraformaldehyde, embedded in paraffin and analysed histologically by H&E staining (×132). PBStreated tumors showed a solid growth pattern without necrosis (A). Tumors treated with ODN1826 (B) or ODN10 (C) exhibited extensive cellular polymorphism, including cavitate nuclei (arrow①), swollen nuclei (arrow②), and apoptosis (arrow③). Figure 7 . Histological analysis of spleen and oxter lymph nodes (HE staining, ×40). The PBS-treated group presented with large-scale necrosis (arrow①) and vasal infarct (arrow②) by a metastatic melanoma mass (arrow③) in the spleen (A), whereas the ODN10 treatment group was normal (B). The PBStreated group showed a metastatic melanoma mass in the vessel of oxter lymph nodes (arrow③) (C), whereas the ODN10 treatment group was normal (D).
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Acta Pharmacologica Sinica npg IgE secretions. We presume that ODN10 can induce pDCmediated cellular adaptive immunity to release large amounts of type I IFN; the latter stimulates T h1 cells to secret IL-2 and IL-12, which induce the CTL precursors to differentiate into antitumor CTL cells and also induce B cells to synthesise antitumor IgG antibodies. Meanwhile, ODN10 can stimulate NK cells responsible for spontaneous cytotoxicity of a variety of tumor cells and can activate macrophages, scavengers of dead cell debris. In addition, our study also demonstrated that the novel ODN10 can reverse established T h2 responses to T h1 -type responses and change an individual's tumor microenvironment, which contributes to identifying and killing tumor cells.
In summary, our experimental results demonstrated that the novel ODN10 has more potent immunomodulatory and antitumor activity towards melanoma than other ODNs, and as such, displays a promising application in cancer immunotherapy in mice. Our study suggests that the palindrome may be essential to the immunostimulatory potency of a CpG ODN and contributes to its antitumor activity.
